News|Videos|February 16, 2024
The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer
Author(s)Laura Huppert, MD, Yara Abdou, MD
The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.
Advertisement
Advertisement
Related to this article
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
The oral PARG inhibitor ETX-19477 earned fast track status for BRCA-mutated, HR-positive, HER2-negative unresectable or metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
2
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Borate on Efficacy Data for Shorter Venetoclax-Plus-Azacitidine Dosing in AML
5